Sanofi has paid big bucks to enter the race to develop a new drug for MS. The drug was developed by Principia Biopharma and crosses the blood-brain barrier making it an attractive candidate not only for MS but for the treatment of other neurological disease.
Sanofi Enters the Race to Develop a New Drug for Multiple Sclerosis
Tweets on this subject
Sanofi has committed up to $805 million to license a preclinical multiple sclerosis drug from Principia Biopharma: https://t.co/U8JT3n6ucA— FierceBiotech (@FierceBiotech) November 9, 2017